Biodelivery sciences international, inc. (BDSI)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Operating activities:
Net loss

-15,305

-33,867

5,285

-

-

-

-

-

-

-

-

Net (loss) income

-

-

-

-67,138

-37,672

-54,218

-57,394

1,652

-23,325

-13,032

33,046

Adjustments to reconcile net loss to net cash flows from operating activities
Depreciation and amortization

-

-

-

-

-

-

-

466

444

422

176

Depreciation

1,846

740

693

437

329

123

207

-

-

-

-

Accretion of debt discount and loan costs

11,508

4,138

2,392

397

500

642

164

-

-

-

-

Amortization of intangible assets

7,000

5,200

5,400

971

970

972

1,140

1,021

890

844

697

Provision for inventory obsolescence

197

-56

243

0

-

-

-

-

-

-

-

Derivative liability

-

-

-

-

-

13,167

-

-

-

-

-

Derivative loss (gain)

-

-

-

-

-

-

121

-5,594

3,463

3,126

-6,790

Impairment loss on equipment

0

78

0

-

-

295

-

-

-

-

-

Stock-based compensation expense

5,416

5,941

14,801

14,931

14,249

6,883

3,327

1,619

1,226

1,376

2,003

Deferred income taxes

0

40

-15,972

-

-

-

-

-

-

-

-

Bargain purchase gain

0

0

27,336

-

-

-

-

-

-

-

-

Purchase of Arcion license with common stock

-

-

-

-

-

-

2,072

-

-

-

-

Changes in assets and liabilities, net of effect of acquisition:
Warrant issuance expense

-

-

-

-

-

-

-

-

-

-

55

Loss on Disposal of Equipment

-

-

-

-

-

-

-

-

-

-

-2

Intangible license impairment

-

-

-

-

-

-

-

-

-

243

-

Warrants received in settlement

-

-

-

-

-

-

-

-

-

-382

-

Accounts receivable

25,163

4,640

5,884

862

-670

347

2,273

420

-530

-635

809

Inventories

6,102

-741

-2,448

810

730

1,828

-

-

-

-

-

Prepaid expenses and other assets

581

-422

-526

203

1,365

2,252

68

-4

-6

-51

-29

Accounts payable and accrued liabilities

32,275

-2,807

6,644

-1,546

5,055

4,325

-656

5,568

407

809

216

Deferred revenue

0

0

-21,716

-

-

-

-

-

-

-

-

Taxes payable

-

-

-

-

-

-

-

129

-

-312

312

Deferred revenue

-

-

-

-159

14,262

3,405

-6,500

-3,446

7

788

-24,330

Net cash flows used in operating activities

-

-

-

-53,982

-3,732

-28,833

-60,102

12,187

-

-

-

Net cash flows used in operating activities

11,072

-24,113

-32,451

-

-

-

-

-

-23,274

-11,682

18,190

Investing activities:
Product acquisitions

30,685

1,951

5,853

-

-

-

-

-

-

-

-

Acquisitions of equipment

79

112

11

405

701

1,603

77

39

286

103

749

Purchase of intangible assets

-

-

-

-

-

-

-

1,050

-

1,000

2,000

Net cash flows used in investing activities

-

-

-

-405

-701

-1,603

-77

-1,089

-

-

-

Net cash flows used in investing activities

-30,764

-2,063

-5,864

-

-

-

-

-

-286

-1,103

-2,749

Financing activities:
Proceeds from sales of securities, net of costs incurred

-

-

-

40

-40

72,662

-

-

-

-

-

Proceeds from sales of securities

-

-

-

-

-

-

-

38,373

-

-

-

Proceeds from exercise of stock options

2,321

670

439

297

755

4,580

357

2,054

349

97

663

Proceeds from issuance of common stock, less underwriters discount

48,000

0

0

2,460

-

-

-

-

13,996

9,747

-

Issuance of warrants

-

-

-

49

-

-

-

-

-

-

-

Proceeds from issuance of Series B preferred stock

0

50,000

0

-

-

-

-

-

-

-

-

Payment on notes payable

-

-

-

-

-

-

-

-

-

-

-76

Proceeds from exercise of common stock warrants

-

-

-

-

1

7,741

50

921

1,749

-

5,108

Payment on note payable

67,346

0

30,000

-

3,335

7,333

-

-

-

-

-

Proceeds from notes payable

59,987

0

60,000

-

20,667

-

20,000

-

-

-

-

Equity finance costs

410

1,417

0

-

-

-

-

-

-

-

-

Return of short swing profits

-

-

-

-

6

82

-

-

-

-

-

Payment of deferred financing fees

0

450

2,948

-

533

-

241

-

-

-

-

Loss on refinancing of former debt

2,794

0

0

-

-

-

-

-

-

-

-

Repayment of related party advances

-

-

-

-

-

-

-

-7

7

-2,723

1,832

Net cash flows (used in) provided by financing activities

-

-

-

2,846

17,521

77,732

20,166

41,341

-

-

-

Net cash flows provided by financing activities

39,758

48,803

27,491

-

-

-

-

-

16,103

7,121

7,527

Net change in cash and cash equivalents

20,066

22,627

-10,824

-

-

-

-

-

-

-

-

Net change in cash and cash equivalents

-

-

-

-51,541

13,088

47,296

-40,013

52,439

-7,458

-5,664

22,967

Cash paid for interest

6,809

6,053

5,285

-

-

-

-

-

-

-

-

Cash paid for interest

-

-

-

2,870

1,885

1,386

742

-

-

-

-

Non-cash Financing and Investing Activities:
Adjustments to additional paid in capital dividends in excess of retained earnings

12,500

12,500

-

-

-

-

-

-

-

-

-

Common stock issuance upon retirement, shares

2,119

2,119

-

-

-

-

-

-

-

-

-

Common stock issuance upon retirement

5,300

5,300

-

-

-

-

-

-

-

-

-

Accrued financing expenses

-

600

-

-

-

-

-

-

-

-

-

Fair value of bargain purchase price of BELBUCA acquisition

-

27,300

27,300

-

-

-

-

-

-

-

-

Cash paid for taxes

-

-

-

-

-

-

80

-

-

-

-

Series B Non-Voting Convertible Preferred Stock
Adjustments to additional paid in capital dividends in excess of retained earnings

12,500

-

-

-

-

-

-

-

-

-

-

Accrued financing expenses

600

-

-

-

-

-

-

-

-

-

-